Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

This trial compares two insulin-based treatment strategies in overweight or obese people with type 2 diabetes that is not well controlled — specifically, whether using a GLP-1 receptor agonist (liraglutide) plus rapid-acting insulin works better than using long-acting insulin (glargine) plus rapid-acting insulin. **You may be eligible if...** - You are between 18 and 75 years old with a BMI between 24 and 45 kg/m² - You have type 2 diabetes that is not well controlled (HbA1c of 9.0% or above if newly diagnosed, or 7.5% or above despite taking at least two oral diabetes medications or current insulin treatment) - You have been diagnosed using standard World Health Organization criteria **You may NOT be eligible if...** - You have a history of pancreatic disease or a specific type of thyroid cancer (medullary thyroid carcinoma) - Your pancreatic enzyme levels (lipase) are more than 3 times above normal - Your kidneys are not functioning well (creatinine clearance at or below 30 mL/min) - You have had a heart attack, stroke, coronary bypass, or severe heart failure in the past 6 months - You are pregnant, trying to become pregnant, or breastfeeding Talk to your doctor to see if this trial is right for you.